Biosimilar Epoetin Zeta in Oncology and Haematology: Development and Experience following 6 Years of Use | Citedby Results | Acta Haematologica | Karger Publishers

Skip to Main Content

Skip Nav Destination

Biosimilar Epoetin Zeta in Oncology and Haematology: Development and Experience following 6 Years of Use

Acta Haematol (2015) 135 (1): 44–52.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Biosimilar erythropoiesis‐stimulating agents are an effective and safe option for the management of myelofibrosis‐related anemia

Elena Inzoli
Elena Crisà
Novella Pugliese
Ivan Civettini
Giuseppe Lanzarone
Andrea Castelli
Vincenzo Martinelli
Laura Montelisciani
Laura Antolini
Carlo Gambacorti‐Passerini
Elena Maria Elli

European Journal of Haematology (2023) 110 (4): 354.

The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions

Charles L. Bennett
Sumimasa Nagai
Andrew C. Bennett
Shamia Hoque
Chadi Nabhan
Martin W. Schoen
William J. Hrushesky
Stefano Luminari
Paul Ray
Paul R. Yarnold
Bart Witherspoon
Josh Riente
Laura Bobolts
John Brusk
Rebecca Tombleson
Kevin Knopf
Marc Fishman
Y. Tony Yang
Kenneth R. Carson
Benjamin Djulbegovic
John Restaino
James O. Armitage
Oliver A. Sartor

The Oncologist (2021) 26 (8): e1418.

Erythropoiesis-Stimulating Agents in the Management of Anemia in Chronic Kidney Disease or Cancer: A Historical Perspective

Matti Aapro
Pere Gascón
Kashyap Patel
George M. Rodgers
Selwyn Fung
Luiz H. Arantes
Jay Wish

Frontiers in Pharmacology (2019) 9

The Impact of Biosimilars in Supportive Care in Cancer

Paul Cornes
Matti Aapro

European Oncology & Haematology (2018) 14 (1): 20.

Biosimilars in Dermatology – theory becomes reality

Sascha Gerdes
Ulrich Mrowietz
Matthias Augustin
Alexander Enk
Klaus Strömer
Michael P. Schön
Marc A. Radtke

JDDG: Journal der Deutschen Dermatologischen Gesellschaft (2018) 16 (2): 150.

Biosimilars in der Dermatologie – Theorie wird Realität

Sascha Gerdes
Ulrich Mrowietz
Matthias Augustin
Ralph von Kiedrowski
Alexander Enk
Klaus Strömer
Michael P. Schön
Marc A. Radtke

JDDG: Journal der Deutschen Dermatologischen Gesellschaft (2018) 16 (2): 150.

Pathogenesis and Treatment Options of Cancer Related Anemia: Perspective for a Targeted Mechanism-Based Approach

Clelia Madeddu
Giulia Gramignano
Giorgio Astara
Roberto Demontis
Elisabetta Sanna
Vinicio Atzeni
Antonio Macciò

Frontiers in Physiology (2018) 9

Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years’ Experience Gained

Matti Aapro
Andriy Krendyukov
Martin Schiestl
Pere Gascón

BioDrugs (2018) 32 (2): 129.

Comparative effectiveness and safety of erythropoiesis-stimulating agents (biosimilars vs originators) in clinical practice: a population-based cohort study in Italy

Francesco Trotta
Valeria Belleudi
Danilo Fusco
Laura Amato
Alessandra Mecozzi
Flavia Mayer
Massimo Sansone
Marina Davoli
Antonio Addis

BMJ Open (2017) 7 (3): e011637.

A retrospective open-label uncontrolled study of Epoetin zeta on the treatment of chemotherapy-induced anemia in solid tumors

Constantinos E. Alifieris
Kyriakos Orfanakos
Aristina Papanota
George P. Stathopoulos
Nikolaos Sitaras
Dimitrios T. Trafalis

Journal of Cancer Research and Clinical Oncology (2017) 143 (4): 717.

History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology

Kamyar Kalantar-Zadeh

American Journal of Nephrology (2017) 45 (3): 235.

Biosimilar epoetin zeta: extrapolation of indications and real world utilization experience

Theodor Dingermann
Florian Scotte

Expert Opinion on Biological Therapy (2016) 16 (7): 967.

Protocolo de transfusión de concentrados de hematíes y empleo de agentes estimulantes de la eritropoyesis

M.J. Moreno Belmonte
A. Martínez Marín
C. Funes Vera
J.M. Moraleda Jiménez

Medicine - Programa de Formación Médica Continuada Acreditado (2016) 12 (20): 1184.